ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

regorafenib

Also written as “Regorafenib (Stivarga, BAY73-4506)”, “Regorafenib” and “Regorafenib (BAY73-4506)”.

Its studies are mostly in Colorectal Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Pancreatic Neoplasms · Gastrointestinal Stromal Tumors, led by 2 companies.

Drug pageRegorafenib: every studyAll 173 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 24, 201833 company-led studies, 1 open or runningNext primary completion: Apr 27, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayerits history only321 open or runningphase 4since May 24, 2018Apr 17, 2008Apr 27, 2028phase 2 · NCT06246643
Sarah Cannon Research Institute10 open or runningphase 2since Apr 21, 2015Apr 21, 2015none ahead

Also a collaborator on its studies: Novartis, Merck, Bristol-Myers Squibb and Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sarah Cannon Research Institute only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 21, 2015First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT02425683 · 24 enrolled · United States

TargetBeta

“Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor; Fibroblast growth factor receptor 1 inhibitor”ChEMBL 37, by rule

Studies

The one study Sarah Cannon Research Institute leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02425683Colorectal Neoplasms · United States2TerminatedSep 21, 201724

How it is read

Names in the registry

  • “Regorafenib (Stivarga, BAY73-4506)”, 21 entries
  • “Regorafenib”, 6 entries
  • “Regorafenib (BAY73-4506)”, 4 entries
  • “TAS-102, Regorafenib , Fruquintinib”, 1 entry
  • “Regorafenib, (Stivarga, BAY73-4506)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.